

Dear Medical Professional,

Sanofi Pasteur will replace its current Tetanus and Diphtheria Toxoids Adsorbed (Td) vaccine, DECAVAC[®], with TENIVAC[™]. TENIVAC vaccine pricing will be the same as DECAVAC vaccine. Availability of TENIVAC vaccine will begin February 1, 2012. While TENIVAC vaccine will be the only Td vaccine offered by Sanofi Pasteur starting February 1, DECAVAC vaccine will remain in the market through various channels until DECAVAC vaccine inventory is depleted.

The Food and Drug Administration (FDA) approved Sanofi Pasteur's vaccine, TENIVAC vaccine, on November 3 2003, for use in persons 7-59 years of age. On June 5, 2008, the FDA approved the use of TENIVAC vaccine in adults 60 years of age and older.

Sanofi Pasteur began pursuing a license for TENIVAC vaccine in 2001 as a secondary option to assure sufficient Td vaccine availability for the US market at that time. Transitioning to TENIVAC vaccine and discontinuing DECAVAC vaccine is a step towards improving manufacturing capacity domestically and globally.

TENIVAC vaccine will be billed using the same CPT^{®a} code, 90714, but will have different National Drug Codes (NDC). The NDCs^b for TENIVAC vaccine will be:

NDC 49281-215-10 / Vial, 1 Dose (10 per package, contains no latex)

NDC 49281-215-15 / Syringe, 1 Dose (10 per package, without needle)

IMPORTANT SAFETY INFORMATION

Indication

TENIVAC vaccine is indicated for active immunization for prevention of tetanus and diphtheria. TENIVAC vaccine is approved for use in persons 7 years of age and older.

Safety Information

The most common local and systemic adverse reactions to TENIVAC vaccine include injection site erythema, tenderness, and swelling; headache, malaise, and fever. Other adverse reactions may occur. TENIVAC vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine following a previous dose of this vaccine or any other tetanus or diphtheria toxoid-containing vaccine. Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with diphtheria or tetanus components should be carried out.

The decision to give TENIVAC vaccine should be based on the potential benefits and risks or if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid. Persons who experienced Arthus-type hypersensitivity reactions following a prior dose of tetanus toxoid-containing vaccine should not receive TENIVAC vaccine less than 10 years since the last dose of tetanus toxoid-containing vaccine. The tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex sensitive individuals. Vaccination with TENIVAC vaccine may not protect all individuals.

Before administering TENIVAC vaccine, please see accompanying full Prescribing Information. Please [Click here](#) for full Prescribing Information.

If you have questions please contact your representative or call 1-800-VACCINE (1-800-822-2463) for Sanofi Pasteur, to answer any product specific questions you may have.

Regards,
Don Tucker
National Accounts Specialist

^a CPT = Current Procedural Terminology is a registered trademark of the American Medical Association.

DECAVAC vaccine is manufactured and distributed by Sanofi Pasteur Inc. TENIVAC vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.

MKT24422-2